Sistematski pregled / meta-analiza 2019
Srce i krvni sudovi

Trajanje dvostruke antiagregacijske terapije nakon perkutane koronarne intervencije sa stentom koji eluira lijek: sistematski pregled i mrežna meta-analiza.

BMJ (Clinical research ed.)

Bosanski prijevod

Sažetak istraživanja

Cilj Procijeniti efikasnost i sigurnost standardne (12 mjeseci) ili dugotrajne (>12 mjeseci) dvostruke antiagregacijske terapije (DAPT) u odnosu na kratkoročnu (Sistematski pregled dizajna i meta-analiza mreže. Izvori podataka Relevantne studije objavljene između juna 1983. i aprila 2018. od Medline, Embase, PubM, Clinic Trials of Science, Libr. ClinicalTrials.gov i Clinicaltrialsregister.eu Uključena su randomizirana kontrolirana ispitivanja koja su upoređivala dva od tri trajanja DAPT (kratkotrajne, standardne i dugotrajne) s DES-om Uključeno je 17 studija (n=46 864), u poređenju sa kratkoročnim DAPT, mrežna meta-analiza je pokazala da je dugotrajna DAPT rezultirala većim stopama krvarenja (omjer šansi 1,78, 95% interval pouzdanosti 1,27 do 2,49) i nesrčana smrtnost (1,53 do 1,63). viša stopa krvarenja (1,39, 1,01 do 1,92) Nije uočena primjetna razlika u drugim primarnim krajnjim tačkama pacijenti sa DES-om nove generacije (1.99, 1.04 do 3.81) kratkoročni DAPT je pokazao sličnu efikasnost i sigurnost kao i kod akutnog koronarnog sindroma (ACS) i nove generacije DES-a DAPT (klopidogrel), dugotrajni DAPT je doveo do većeg krvarenja i nesrčane smrti, a standardni termin DAPT je bio povezan s povećanim rizikom od krvarenja trajanje DAPT-a treba uzeti u obzir lične rizike od ishemije i krvarenja, ova studija je sugerirala da se kratkoročni DAPT može razmotriti za većinu pacijenata nakon PCI sa DES-om, kombinujući dokaze iz direktnih i indirektnih poređenja PROSPERO CRD42018099519.

Prikaži originalni naslov i sažetak na engleskom

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.

Objective To evaluate the efficacy and safety of standard term (12 months) or long term (>12 months) dual antiplatelet therapy (DAPT) versus short term (

Design Systematic review and network meta-analysis. Data sources Relevant studies published between June 1983 and April 2018 from Medline, Embase, Cochrane Library for clinical trials, PubMed, Web of Science, ClinicalTrials.gov, and Clinicaltrialsregister.eu. Review methods Randomised controlled trials comparing two of the three durations of DAPT (short term, standard term, and long term) after PCI with DES were included. The primary study outcomes were cardiac or non-cardiac death, all cause mortality, myocardial infarction, stent thrombosis, and all bleeding events.

Results 17 studies (n=46 864) were included. Compared with short term DAPT, network meta-analysis showed that long term DAPT resulted in higher rates of major bleeding (odds ratio 1.78, 95% confidence interval 1.27 to 2.49) and non-cardiac death (1.63, 1.03 to 2.59); standard term DAPT was associated with higher rates of any bleeding (1.39, 1.01 to 1.92). No noticeable difference was observed in other primary endpoints. The sensitivity analysis revealed that the risks of non-cardiac death and bleeding were further increased for ≥18 months of DAPT compared with short term or standard term DAPT. In the subgroup analysis, long term DAPT led to higher all cause mortality than short term DAPT in patients implanted with newer-generation DES (1.99, 1.04 to 3.81); short term DAPT presented similar efficacy and safety to standard term DAPT with acute coronary syndrome (ACS) presentation and newer-generation DES placement. The heterogeneity of pooled trials was low, providing more confidence in the interpretation of results.

Conclusions In patients with all clinical presentations, compared with short term DAPT (clopidogrel), long term DAPT led to higher rates of major bleeding and non-cardiac death, and standard term DAPT was associated with an increased risk of any bleeding. For patients with ACS, short term DAPT presented similar efficacy and safety with standard term DAPT. For patients implanted with newer-generation DES, long term DAPT resulted in more all cause mortality than short term DAPT. Although the optimal duration of DAPT should take personal ischaemic and bleeding risks into account, this study suggested short term DAPT could be considered for most patients after PCI with DES, combining evidence from both direct and indirect comparisons. Systematic review registration PROSPERO CRD42018099519.

Autorstvo i publikacija

Autori

Yin SH, Xu P, Wang B, Lu Y, Wu QY, Zhou ML, Wu JR, Cai JJ, Sun X, Yuan H.

Časopis
BMJ (Clinical research ed.)
Vrste publikacije
Komparativna studija, Istraživačka podrška vlade izvan SAD-a, Istraživački članak, Sistematski pregled, Mrežna meta-analiza, Članak u časopisu
Licenca
CC BY-NC
Citiranja u Europe PMC
77
Provjerljivi identifikatori

Izvorni podaci

DOI
10.1136/bmj.l2222
PMID
31253632
PMCID
PMC6595429
Provjereno
2026-07-26
Otvori cijeli rad u Europe PMC
Napomena o bosanskom prijevodu

Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.

Pregledaj originalni članak na engleskom
Istraživački zapis služi za informiranje i istraživanje. Ne zamjenjuje medicinski savjet, dijagnozu ili preporuku liječenja.